Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies

Keyphrases

• Treatment Strategy 100%
• Bone Loss 100%
• Patients with Breast Cancer 100%
• Aromatase Inhibitors 100%
• Postmenopausal Women 75%
• Zoledronic Acid 50%
• Bisphosphonates 50%
• Bone Turnover 50%
• Patient Management 25%
• Quality of Life 25%
• Risk Factors 25%
• Bone Mineral Density 25%
• Aromatase Inhibitor Therapy 25%
• Low Bone Mineral Density 25%
• Intervention Strategies 25%
• Bone Health 25%
• Functional Independence 25%
• Early Breast Cancer 25%
• Aromatase Inhibitor-associated Bone Loss 25%
• Vitamin D Supplementation 25%
• Health Management 25%
• Functional Quality 25%
• Hormone Receptor-positive Breast Cancer 25%
• Inhibitor Treatment 25%
• Fragility Fracture 25%
• Healthy Lifestyle 25%
• Endometrial Cancer 25%
• Treatment Algorithm 25%

Medicine and Dentistry

• Breast Cancer 100%
• Osteolysis 100%
• Aromatase Inhibitor 100%
• Zoledronic Acid 40%
• Bone Density 40%
• Bone Turnover 40%
• Postmenopause 40%
• Bisphosphonate 40%
• Supplementation 20%
• Isotopes of Calcium 20%
• Fragility Fracture 20%
• Quality of Life 20%
• Premenopause 20%
• Vitamin D 20%
• Tamoxifen 20%
• Healthy Lifestyle 20%
• Endometrial Cancer 20%
• Hormone Receptor 20%
• Health Care Management 20%